natgillin/translations-raw huggingface dataset:
2 This adverse reaction was not observed in the Phase 3 clinical studies for Genvoya but identified from clinical studies for elvitegravir when used with other antiretrovirals.
2 Ova nuspojava nije uočena u fazi 3 kliničkih ispitivanja lijeka Genvoya ali je prepoznata u kliničkim ispitivanjima elvitegravira kad se koristio s drugim antiretrovirusnim lijekovima
2 This adverse reaction was not observed in the Phase 3 studies of emtricitabine+tenofovir alafenamide in combination with elvitegravir+cobicistat but identified from clinical studies or post-marketing experience of emtricitabine when used with other antiretrovirals.
2 Ova nuspojava nije uočena u fazi 3 ispitivanja emtricitabina+tenofoviralafenamida u kombinaciji sa elvitegravirom+kobicistatom, ali je prepoznata u kliničkim ispitivanjima ili iskustvima nakon stavljanja u promet za emtricitabin kad se koristi s drugim antiretrovirusnim lijekovima.
2 to 10 years of age
2 do 10 godina
2 to 12 years
2 do 12 godina
2 to 12 years
2-12 godina
2 to 12 years (N=14)
2-12 godina
2 to 12 years (N=19)
2-12 godina
2 to 15 years old
u dobi od 2 do 15 godina
2 to < 12 years (n = 23)
2 do < 12 godina (n = 23)
2 to < 6 years
2 do < 6 godina
2 to <12 years (n=10)
od 2 do <12 godina (N = 10)
2 to <6 y
2 do < 6 god
2 To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process
2 Kada je potvrđeno ili se sumnja da anaerobni patogeni pridonose razvoju infekcije, primjenjivati u kombinaciji s metronidazolom
2 transdermal patches
2 transdermalna flastera
2 tubes
2 tube
2 units selected
2 jedinice
2 Urinary tract infection includes the following preferred terms: urinary tract infection, Escherichia urinary tract infection, pyelonephritis, and prostatitis.
2 Infekcija mokraćnog sustava uključuje sljedeće preferirane pojmove: infekcija mokraćnog sustava, infekcija mokraćnog sustava čiji je uzročnik Escherichia, pijelonefritis, i prostatitis.
2 vial adapters
2 nastavka za bočice
2 vial adapters
2 nastavka za bočicu
2 vials + 12 injection syringes + 12 injection needles + 24 cleansing swabs
2 bočice + 12 štrcaljki za injekciju + 12 igala za injekciju + 24 tupfera za čišćenje
2 vials + 12 injection syringes with attached needle + 24 cleansing swabs
2 bočice + 12 štrcaljki za injekciju s pričvršćenom iglom + 24 tupfera za čišćenje
2 vials + 12 injection syringes with attached needle and needle protection device + 24 cleansing swabs
2 bočice + 12 štrcaljki za injekciju s pričvršćenom iglom i uređajem za zaštitu igle + 24 tupfera za čišćenje
2 vials 6 vials 10 vials
2 bočice 6 bočica 10 bočica
2 vials of 0.6 mL
2 bočice od 0,6 ml
2 vials of 10 ml
2 bočice od 10 ml
2 vials of 50 mL solution for injection/infusion each
2 bočice od 50 ml otopine za injekciju/infuziju svaka
2 vials of Cinryze 500 Units powder for solution for injection 2 vials of water for injections (5 ml each)
2 bočice lijeka Cinryze 500 jedinica prašak za otopinu za injekciju 2 bočice vode za injekciju (5 ml svaka)
2 vials of powder
2 bočice s praškom
2 vials with 2 sterile 1 mL injection syringes with retractable injection needle and 4 alcohol swabs; or
2 bočice s 2 sterilne štrcaljke za injekciju od 1 ml s iglom za injekciju na uvlačenje i 4 alkoholom natopljena jastučića; ili
2 Week Follow-up
nakon 2 tjedna praćenja
2 week- treatment free interval (Days 29 – 42)
Period bez liječenja u trajanju od 2 tjedna (Dani 29 – 42)
2 weeks after a single vaccination from 12 weeks of age for rabies,
2 tjedna nakon jednog cijepljenja, od 12. tjedana starosti za bjesnoću,
2 weeks after a single vaccination from 12 weeks of age for rabies,
2 tjedna nakon prvog cijepljenja za bjesnoću, od 12 tjedna starosti,
2 weeks after cessation of treatment with St. John’s wort.
2 tjedna nakon prekida liječenja Gospinom travom.
2 weeks after EOT
2 tjedna po završetku liječenja
2 weeks after your 1st treatment
2 tjedna nakon 1. doze
2 weeks n=279
2 tjedna n=279
2 weeks, reduce further to 300 mg. unrelated to leukaemia, stop imatinib until
Ako citopenija potraje 2 tjedna, dozu ponovno smanjiti na
2 What you need to know before you take CELSENTRI
Što morate znati prije nego počnete uzimati CELSENTRI
2 With gross residual disease.
2 Uz veliki rezidualni tumor
2 With or without gross residual disease.
2 Uz veliki rezidualni tumor ili bez njega
2 x (30 capsules +
2 x (30 kapsula +
2 x (5 x 3 ml) Humalog Mix25 cartridges for a 3 ml pen.
2 x (5 x 3 ml) uložaka lijeka Humalog Mix25 za brizgalicu od 3 ml
2 x (5 x 3 ml) Humalog Mix50 100 U/ml KwikPens.
2 x (5 x 3 ml) Humalog Mix50 100 U/ml KwikPen brizgalica
2 x (5 x 3 ml) Humalog Mix50 cartridges for a 3 ml pen.
2 x (5 x 3 ml) uložaka lijeka Humalog Mix50 za brizgalicu od 3 ml
2 x (5 x 3 ml) Liprolog Basal 100 units/ml KwikPens
2 x (5 x 3 ml) Liprolog Basal 100 jedinica/ml KwikPen brizgalica
2 x (5 x 3 ml) Liprolog Mix50 100 units/ml KwikPens.
2 x (5 x 3 ml) Liprolog Mix50 100 jedinica/ml KwikPen brizgalica
2 x (5 x 3 ml) Liprolog Mix50 cartridges for a 3 ml pen.
2 x (5 x 3 ml) uložaka lijeka Liprolog Mix50 za brizgalicu od 3 ml
2 x 0.25 mL injections, or
2 x 0,25 mL injekcije, ili
2 x 0.5 mL injections
2 x 0,5 mL injekcije
2 x 1 orodispersible tablets in alu/alu perforated unit dose blisters, 4 x 1 orodispersible tablets in alu/alu perforated unit dose blisters, 8 x 1 orodispersible tablets in alu/alu perforated unit dose blisters.
2 x 1 raspadljive tableta za usta u al/al perforiranim blisterima djeljivima na jedinične doze, 4 x 1 raspadljive tableta za usta u al/al perforiranim blisterima djeljivima na jedinične doze, 8 x 1 raspadljivih tableta za usta u al/al perforiranim blisterima djeljivima na jedinične doze.
2 x 1 tablets (unit
2 x 1 tableta (s jediničnim dozama)
2 x 1 tablets (unit dose)
2 x 1 tablete (jedinična doza)
2 x 10 ml Humalog vials.
2 x 10 ml bočice lijeka Humalog
2 x 10 ml Liprolog vials.
2 x 10 ml bočice lijeka Liprolog
2 x 100 mg twice daily
2 x 100 mg dvaput na dan
2 x 1620 mg tablets
2 tablete od 1620 mg
2 x 2,000
2 x 2.000
2 x 4,000
2 x 4.000
2 x 80 mg hard capsule
2 x 80 mg tvrdu kapsulu
2 x baseline and
2 x početna
2 x baseline and
vrijednost i
2 x/week dosing
doziranje 2 x tjedno
2 year
2 godine
2 Year
2. godini
2 years
3 godine.
2 years
godine
2 years
godine.
2 years if bottle is unopened.
2 godine ako je bočica neotvorena.
2 years when stored in a freezer ( -20˚C ±5°C).
2 godine kada se čuva u zamrzivaču ( -20˚C ±5°C) .
2 years.
godine
2 years.
godine.
2) after 48-weeks were increased ASAT (6.1%), increased ALAT (9.7%), increased amylase (6.0%), increased cholesterol (4.2%), increased triglycerides (24.9%), and decreased white blood cell count (5.7%).
48 tjedana bile su: povišenje AST (6,1%), povišenje ALT (9,7%), povišenje amilaza (6,0%), povišeni kolesterol (4,2%), povišeni trigliceridi (24,9%) i smanjeni broj leukocita (5,7%).
2) and place it on top of the bottle.
2) i postavite ju na vrh boce.
2) and place it on top of the bottle.
2) i postavite ju na vrh bočice.
2) and placed on top of the bottle, sliding the plastic dip tube carefully into the bottle.
2) i postaviti na vrh boce kližući plastičnu tubu pažljivo u bocu.
2) and placed on top of the bottle, sliding the plastic dip tube carefully into the bottle.
2) i postaviti na vrh bočice, kližući plastičnu cjevčicu pažljivo u bočicu.
2, 3 months
2, 3 mjeseca
2, 4 months
2, 4 mjeseca
2, 4, + 13 months
2, 4, + 13 mjeseci
2, 4, 6, 12 months
2, 4, 6, 12 mjeseci
2, increase the dinutuximab infusion to 1.75 mg/m2/h.
mg/m2/sat. primjene GM-CSF-a ili IL-2, povećati brzinu infuzije dinutuksimaba na 1,75 mg/m2/sat.
2, light peach opaque cap and white opaque body, hard-shell gelatin capsule filled with white to off-white powder.
2 sa svjetloružičastom neprozirnom kapicom i bijelim neprozirnim tijelom napunjena bjeličastim prahom.
2, rue du Colonel Lilly F-67640 Fegersheim France
2, rue du Colonel Lilly F-67640 Fegersheim Francuska
2, Sept 2009) on the basis of an estimated upper bound of the 95% confidence interval for 0 events given the number of patients treated with efavirenz in these clinical trials (n=3,969).
2. rujna 2009.) na temelju procjene gornje granice 95% tnog intervala pouzdanosti za 0 događaja, uzimajući u obzir broj ispitanika liječenih efavirenzom u tim kliničkim ispitivanjima (n=3969).
2, Sept 2009) on the basis of an estimated upper bound of the 95% confidence interval for 0 events given the number of patients treated with efavirenz in these clinical trials (n=3,969).
2. rujna 2009.) na temelju procjene gornje granice 95%-tnog intervala pouzdanosti za 0 događaja, uzimajući u obzir broj ispitanika liječenih efavirenzom u tim kliničkim ispitivanjima (n=3969).
2,000 doses
2.000 doza
2,000 doses
2000 doza
2,000 IU/1 ml
2000 IU/1 ml
2,000 IU/ml:
2000 IU/ml:
2,000 mg dose - Use 2 vials (100 ml total, 50 ml per vial):
Doza od 2000 mg – koristite 2 bočice (100 ml ukupno, 50 ml po bočici):
2,000 mg dose – Use 2 x 1,000 mg/50 ml vials (100 ml total, 50 ml per vial):
Doza od 2000 mg – koristite 2 bočice od 1000 mg/ 50 ml (100 ml ukupno, 50 ml po bočici):
2,000 mg/day
2000 mg/dan
2,000 mg/m2
2000 mg/m2
2,000 µg/kg
2.000 µg/kg
2,032.0
U/l)
2,051.0
Parametar Placebo
2,234.5
C04-001 C04-002
2,4,6 months
2.,4.,6. mjesec
2,400 mg/m2
2400 mg/m2
2,500 doses
2.500 doza.
2,500 doses
2500 doza
2,500 – 8,000 PFU*
2.500 – 8.000 PFU
2- to 5-year-olds
od 2 do 5 godina
2- to 5-year-olds (<14 kg)
od 2 do 5 godina (<14 kg)
2- to 5-year-olds (≥14 kg to <25 kg)
od 2 do 5 godina (≥14 kg do <25 kg)
2-3-4 months
2-3-4 mjeseca
2-4 months
2-4 mjeseca
2-4-6 months
2-4-6 mjeseci
2-5 years
2 do 5 godina
2-dose infant series: 99% Completed schedule:100%
Serija s 2 doze za dojenčad: 99% završeno cijepljenje:100
2-hydroxy atorvastatin: AUC: 0 35% (0 13 to 0 40)
AUC: ↓ 35% (↓ 13 do ↓ 40)
2-hydroxy atorvastatin: AUC: ↓ 35% (↓ 13 to ↓ 40)
AUC: ↓ 35% (↓ 13 do ↓ 40)
2-hydroxy-3-O-methyl naltrexone and 2-hydroxy-3-O-methyl-6-beta-naltrexol, believed to be mediated by catechol-O-methyl transferases (COMT), and glucuronidation, thought to be mediated by UGT1A1 and UGT2B7.
2-hidroksi-3-O-metil-6-beta-naltreksola, vjerojatno posredstvom katekol-O-metill transferaze (COMT), i glukuronidacijom vjerojatno posredstvom UGT1A1 i UGT2B7.
2-month pack comprising 28 (2x14) single packs, each containing:
Dvomjesečno pakiranje s 28 (2x14) pojedinačnih pakiranja, svako sadrži:
2-month packs comprising 2x14 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or
pakiranje za 2 mjeseca s 2x14 pojedinačnih pakiranja od kojih svako sadrži 1 bočicu s praškom, 1 napunjenu štrcaljku s otapalom, 1 nastavak za bočicu s iglom, 2 tupfera natopljena alkoholom ili
2-OH-atorvastatin AUC 2.29 (2.08-2.52) ↑
2-OH-atorvastatin AUC 2,29 (2,08-2,52) 
2-OH-atorvastatin Cmax 1.98 (1.70-2.31) ↑
2-OH-atorvastatin Cmax 1,98 (1,70-2,31) 
2-OH-atorvastatin Cmin not studied
2-OH-atorvastatin Cmin nije ispitano
2-phenoxyethanol Water for injections
2-fenoksietanol voda za injekcije
2-Sided p-value
Dvostrana p- vrijednost
2-week treatment initiation pack
Dvotjedno pakiranje za početak terapije
2-week treatment initiation pack (63 capsules):
Pakiranje za 2-tjedni početak liječenja (63 kapsule):
2-week treatment pack of 280 hard capsules and 2 inhalers
Pakovanje za 2-tjedno liječenje s 280 tvrdih kapsula i 2 inhalatora
2-year estimate (%)
dvogodišnja procjena (%)
2-year OS rate, % (95% CI)
1-godina stopa ukupnog 77,6 (71,4; 82,7)
2-year Survival (%)
dvogodišnje preživljenje
2.) Using a 1 ml insulin syringe with a 25- to 26-G needle, place a hanging drop (7-10 µl) of [90Y]- radiolabelled Zevalin onto the ITLC strip at its origin.
2.) Pomoću inzulinske štrcaljke volumena 1 ml s iglom od 25-26 G ispustite kap (7-10 µl) [90Y]-radioaktivno označenog Zevalina na trakicu za ITLC na njezinu početku.
2.0 m vs 2.6 m
2,0 m vs 2,6 m
2.0 m vs 2.7 m p=0.1041
2,0 m vs 2,7 m
2.0 ml (or 3.0 ml)
(graduacija po
2.0 ml (or 3.0 ml)
2,0 ml
2.0 ml containing 1.00 mg fentanyl ensuring the delivery of 10 doses of 50 micrograms
2,0 ml sadrži 1,00 mg fentanila i osigurava unos 10 doza od 50 mikrograma.
2.0 ml containing 2.00 mg fentanyl ensuring the delivery of 10 doses of 100 micrograms
2,0 ml sadrži 2,00 mg fentanila i osigurava unos 10 doza od 100 mikrograma.
2.0 ml containing 4.00 mg fentanyl ensuring the delivery of 10 doses of 200 micrograms
2,0 ml sadrži 4,00 mg fentanila i osigurava unos 10 doza od 200 mikrograma.
2.0 ml once daily
1,7 ml jednom dnevno
2.0 ml once daily
2,3 ml jednom dnevno
2.0 ml or 3.0 ml
2,0 ml ili 3,0 ml
2.0 ml twice daily
1,7 ml dvaput dnevno
2.0 ml twice daily
2,3 ml dvaput dnevno
2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate.
2,0 ml/100 kg tjelesne mase) u kombinaciji s antibiotskom terapijom, kako je odgovarajuće.
2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate.
2,0 ml/100 kg tjelesne mase) u kombinaciji s terapijom antibioticima, po potrebi.
2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate.
2,0 ml/100 kg tjelesne težine) u kombinaciji s antibiotskom terapijom, kako je odgovarajuće.
2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate.
2,0 ml/100 kg tjelesne težine) u kombinaciji s antibiotskom terapijom, po potrebi.
2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate.
2,0 ml/100 kg tjelesne težine) u kombinaciji s terapijom antibioticima, kako je odgovarajuće.
2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate.
2.0 ml / 100 kg tjelesne mase u kombinaciji s odgovarajućim antibiotskim liječenjem.
2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate.
2.0 ml/ 100 kg tjelesne mase u kombinaciji s odgovarajućim antibiotskim liječenjem.
2.0 ml/150 kg body weight) in combination with antibiotic therapy, as appropriate.
2,0 ml/150 kg tjelesne mase) u kombinaciji s antibiotskom terapijom, kako je odgovarajuće.
2.0 ml/25 kg body weight).
2,0 ml/25 kg tjelesne mase).
2.0 ml/25 kg body weight).
2,0 ml/25 kg tjelesne težine).
2.0% (0.1% fatal) a
2,0% (0,1% smrtonosna)a
2.0%) and decreases in neutrophils (5.0% vs 7.4%) and white blood cell count (2.0% vs 4.3%).
(3,7% prema 2,0%), aspartat aminotransferaze (AST) (3,2% prema 2,0%) i smanjenja neutrofila (5,0% prema 7,4%) i broja bijelih krvnih stanica (2,0% prema 4,3%).
2.00 (1.56, 2.55) , P<0.0001
117/1026 (11,4%)
2.03 (n=65)
(n=65)
2.06f (1.41, 3.00)
< 0,0001c
2.1 (1.9, 3.1)b
2,1 (10,9; 3,1)b
2.125 mg/kg bodyweight
2,125 mg/kg tjelesne mase
2.13 mg propyl parahydroxybenzoate (E216) Each 15 ml vial of diluent contains:
Svaka bočica otapala od 15 mL sadrži:
2.2 Pneumonia
Upala pluća
2.2 µg of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F
2,2 µg polisaharida za serotipove 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F i 23F
2.2% (95% CI = -5.0%, 9.3%)
2,2% (95% CI = -5,0%, 9,3%)
2.20-fold, respectively, compared to matching healthy subjects.
3,08 puta, a izloženosti slobodnih koncentracija valsartana povećale su se za 1,09 odnosno 2,20 puta, u usporedbi s odgovarajućim zdravim ispitanicima.
2.25 g/dose.
2,25 g/dozi.
2.25 mg, 3 mg, 3.75 mg or 4.5 mg pramipexole dihydrochloride monohydrate, respectively.
2,25 mg, 3 mg, 3,75 mg odnosno 4,5 mg pramipeksoldiklorid hidrata.
2.25 micrograms (once weekly) of Aranesp per kilogram of your body weight.
2,25 mikrograma (jednom tjedno) Aranespa po kilogramu vaše tjelesne težine.
2.3 ml once daily
1,9 ml jednom dnevno
2.3 ml once daily
2,3 ml jednom dnevno
2.3 ml twice daily
1,9 ml dvaput dnevno
2.3 ml twice daily
2,3 ml dvaput dnevno
2.3 – 6.4 RP*
2,3 – 6,4 RP
2.3-6.4 RP
2,3-6,4 RP
2.3. Acute Otitis Media (AOM)
Akutni otitis media (AOM)
2.3. The pharmacokinetics of prucalopride is dose-proportional within and beyond the therapeutic range (tested up to 20 mg).
Farmakokinetika prukaloprida razmjerna je dozi unutar i izvan terapijskog raspona (ispitano za doze do 20 mg).
2.30 (1.83, 2.90) , P<0.0001
138/1009 (13,7%)
2.34 (1.42, 3.87); 0.001a
34,6 (26,4, 43,6)
2.39f (1.43-3.99)
2,39f (1,43; -3,99)
2.4 Impact on nasopharyngeal carriage (NPC)
Utjecaj na nazofaringealno kliconoštvo
2.4 years
2,4 godine
2.4% subcutaneous The incidence of treatment-induced/enhanced anti-rHuPH20 antibodies, only measured in patients in the subcutaneous arm was 10.6%.
Incidencija liječenjem izazvanog/pospješenog stvaranja antitijela na rHuPH20, koja se određivala samo u bolesnika liječenih supkutanom formulacijom, iznosila je 10,6%.
2.4%), alanine aminotransferase (ALT) (3.7% vs 2.0%), aspartate amino transferase (AST) (3.2% vs
6,6%), triglicerida (9,2% prema 5,8%), glukoze (3,5% prema 2,4%), alanin aminotransferaze (ALT)
2.42 [0.53, 4.31]; P = 0.012 c
2,42 [0,53, 4,31]; P = 0,012 c
2.42- 2.91 mmol/L (7.5-9 mg/dl)
2,42 - 2,91 mmol/l (7,5-9 mg/dl)
2.48 mM
2,48 mM
2.5 (therapeutic range 2.0 to 3.0)
Varfarin titriran do ciljnog INR-a od 2,5 (terapijski raspon od 2,0 do 3,0)
2.5 hours
2,5 sati
2.5 mg (N=840)
2,5 mg (N=840)
2.5 mg can be taken with or without food
od 2,5 mg može se uzimati s hranom ili bez nje
2.5 mg daily may be considered.
2,5 mg dnevno.
2.5 mg desloratadine/120 mg pseudoephedrine sulphate
2,5 mg desloratadina/120 mg pseudoefedrinsulfata
2.5 mg every other day (days 1-28 of repeated 28-day cycles)
2,5 mg jednom dnevno
2.5 mg every other day 1-28 every 28 days
2,5 mg svaki drugi dan od 1. do 28. dana svakih 28 dana
2.5 mg film-coated tablets are pale yellow to light yellow, biconvex, round.
Filmom obložene tablete od 2,5 mg su blijedožute do svijetložute boje, bikonveksne, okrugle.
2.5 mg once daily
2,5 mg jednom dnevno
2.5 mg once daily (days 1-28 of repeated 28-day cycles)
2,5 mg jednom dnevno (od 1. do 28. dana u ponavljajućim 28-dnevnim ciklusima)
2.5 mg once daily on days 1-28 every 28 days
2,5 mg jednom dnevno od 1. do 28. dana svakih 28 dana
2.5 mg once every other day (days 1-28 of repeated 28-day cycles)
2,5 mg jednom svaki drugi dan (od 1. do 28. dana u ponavljajućim 28-dnevnim ciklusima)
2.5 mg tablet: red-orange, round, biconvex tablets of 6 mm, marked with the Bayer cross on one side and 2.5 and an “R” on the other side.
2,5 mg tableta: crvenonarančaste, okrugle, bikonveksne tablete od 6 mm, označene Bayerovim križem s jedne strane te brojem 2.5 i slovom “R” s druge strane.
2.5 mg tablets are available in pack sizes of 14, 28, or 98 film-coated tablets in non-perforated calendar blisters and 30x1 or 90x1 film-coated tablets in perforated unit dose blisters.
Tablete od 2,5 mg su dostupne u pakiranjima od 14, 28, ili 98 filmom obloženih tableta u neperforiranim kalendarski označenim blisterima te u pakiranjima od 30x1 ili 90x1 filmom obloženih tableta u perforiranim blisterima djeljivima na jedinične doze.
2.5 mg twice a week (days 1-28 of repeated 28-day cycles)
(od 1. do 21. dana u ponavljajućim 28-dnevnim ciklusima)
2.5 mg twice a week (days 1-28 of repeated 28-day cycles)
2,5 mg dvaput tjedno (od 1. do 28. dana u ponavljajućim 28-dnevnim ciklusima)
2.5 mg twice daily
2,5 mg dva puta na dan
2.5 mg twice daily*
2,5 mg dva puta na dan
2.5 mg, 5 mg, 7.5 mg and 10 mg tablets: Opadry white containing hypromellose (E464), titanium dioxide (E171), lactose monohydrate, polyethylene glycol 3000 and glycerol triacetate
2,5 mg , 5 mg , 7.5 mg i 10 mg tablete : Opadry bijeli sadrži hipromeloze ( E464 ) , titan dioksid ( E171 ) , laktoza monohidrat , polietilen glikol 3000 i glicerola triacetatna
2.5 ml
Potkožno
2.5 mL (10 million
2,5 ml (10 milijuna IU/ml)
2.5 mL (10 million IU/mL)
2,5 ml (10 milijuna IU/ml)
2.5 ml (half 5 ml vial)
2,5 ml (pola bočice od 5 ml)
2.5 mL [for reconstitution of strengths 250/500/1000 IU] 5 mL [for reconstitution of strengths 2000/3000 IU]
2,5 ml [za pripremu za primjenu jačina 250/500/1000 IU] 5 ml [za pripremu za primjenu jačina 2000/3000 IU]
2.5 mL [for reconstitution of strengths 250/500/1000 IU] 5 mL [for reconstitution of strengths 2000/3000 IU]
2,5 ml [za pripremu za primjenu jačina od 250/500/1000 IU] 5,0 ml [za pripremu za primjenu jačina od 2000/3000 IU]
2.5 ml once daily
2,1 ml jednom dnevno
2.5 mL oval Polypropylene (PP) or Low Density Polyethylene (LDPE) bottle and PP or LDPE dispensing plug with PP screw cap, presented in an overwrap.
Ovalna bočica od polipropilena ili polietilena niske gustoće volumena 2,5 ml, s nastavkom za kapanje od polipropilena ili polietilena niske gustoće i polipropilenskim zatvaračem s navojem, u vrećici.
2.5 ml per vial
2,5 ml po bočici.
2.5 ml per vial.
2,5 ml po bočici.
2.5 ml presentation
Pakovanje od 2,5 ml
2.5 ml twice daily
2,1 ml dvaput dnevno
2.5 ml twice daily
2,5 ml dva puta dnevno
2.5 ml twice daily
2,5 ml dvaput dnevno
2.5 mL vials (Ph.
Bočice od 2,5 mL (Ph.
2.5 mL.
2,5 ml.
2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
2,5 ml/100 kg tjelesne mase) u kombinaciji s antibiotskom terapijom ili oralnom rehidracijskom terapijom, kako je odgovarajuće.
2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
2,5 ml/100 kg tjelesne mase) u kombinaciji s antibiotskom terapijom ili peroralnom rehidracijskom terapijom, po potrebi.
2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
2,5 ml/100 kg tjelesne mase) u kombinaciji s terapijom antibioticima ili oralnom rehidracijskom terapijom, kako je odgovarajuće.
2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
2,5 ml/100 kg tjelesne težine) u kombinaciji s antibiotskom terapijom ili oralnom rehidracijskom terapijom, kako je odgovarajuće.
2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
2,5 ml/100 kg tjelesne težine) u kombinaciji s antibiotskom terapijom ili peroralnom rehidracijskom terapijom, kako je odgovarajuće.
2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
2,5 ml/100 kg tjelesne težine) u kombinaciji s antibiotskom terapijom ili peroralnom rehidracijskom terapijom, po potrebi.
2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
2,5 ml/100 kg tjelesne težine) u kombinaciji s terapijom antibioticima ili oralnom rehidracijskom terapijom, kako je odgovarajuće.
2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
2.5 ml / 100 kg tjelesne mase), po potrebi u kombinaciji s antibiotskim liječenjem ili peroralnom rehidracijom.
2.5 ml/150 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
2,5 ml/150 kg tjelesne mase) u kombinaciji s antibiotskom terapijom ili oralnom rehidracijskom terapijom, kako je odgovarajuće.
2.5 ml/vial.
2,5 ml/bočica.
2.5 or 5 ml solution in a single colourless 10 ml glass vial sealed with a rubber closure and metal overseal.
2,5 ili 5 m l otopine u bezbojnoj staklenoj bočici od 10 ml zatvorenoj gumenim čepom i metalnim prstenom.
2.5 to < 5
2,5 do < 5
2.5 to < 6
2,5 do < 6
2.5 to less than 6
2,5 do manje od 6
2.5 x ULN*
2,5 x GGN
2.5 x ULN*
> 10 x GGN
2.5 x ULN**
2,5 x GGN
2.5 year
2,5 godine
2.5 years
2,5 godine
2.5% (95% CI: -2.2%, 7.1%)
2,5% (95% CI: (-2,2%; 7,1%))
2.5% (95% CI: -2.2%, 7.1%)
2,5% (95% CI: -2,2%; 7,1%)
2.6 mg/kg once daily
2,6 mg/kg jedanput na dan
2.6% d
2,6% d
2.6% vs 0%
2,6% vs 0
2.6-5.0 × ULN (Grade 3)
2,6-5,0 × GGN (stupanj 3)
2.66 (1.55, 4.57);
2,34 (1,42; 3,87); 0,001a
2.66 p < 0.0001
2,66 p<0,0001
2.6–4.8 log10 CCID50*
2,6-4,8 log10 CCID50
2.6–4.8 log10 CCID50.
2,6-4,8 log10 CCDI50
2.7 (2.2 - 3.1)
(N = 264)
2.7 m vs 2.6 m
2,7 m vs 2,6 m
2.7 mL
2,7 mL
2.7 ml pre-filled syringe
2,7 ml napunjena štrcaljka
2.7 ml/100 kg) in combination with antibiotic therapy, as appropriate.
2,7 ml/100 kg) u kombinaciji s antibiotskom terapijom, kako je odgovarajuće.
2.7 points [95% CI 1.3-4.0]), after 10 weeks of treatment.
Pediatric Anxiety Rating Scale, PARS) (srednja vrijednost razlike između duloksetina i placeba iznosila je 2,7 bodova [95% CI 1,3-4,0]) nakon 10 tjedana liječenja.
2.75 fold decrease
niženje za 2,75 puta
2.8 (P=0.0152)
2,8 (P = 0,0152)
2.8 ml once daily
2,3 ml jednom dnevno